Study summary
Sacituzumab govitecan beat chemo for people who cannot have immunotherapy
9.7months without progression, vs 6.9 with chemotherapy
What was tested
Sacituzumab govitecan against chemotherapy as first treatment for advanced TNBC in people who could not receive PD-1 or PD-L1 immunotherapy.
What they found
- Median progression-free survival was 9.7 vs 6.9 months.
- Responses lasted longer (12.2 vs 7.2 months).
- Low white blood cell counts (43%) and diarrhea (9%) were the main severe side effects.
What it means
Moves sacituzumab govitecan from later treatment to first treatment for many patients.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.